Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with…more
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with…more
Latest RNS from Oxford Biomedica plc
Analyst consensus: Buy
As of 21 Jul 2026, 8 analysts rate Oxford Biomedica plc a Buy, with 88% buy ratings and a mean price target of 842p (range 550p–1,140p), +39% vs the current price.